-
Anagliptin Vasorelaxation: Kv Channels and SERCA
2026-09-19
A 2025 Acta Diabetologica study shows that Anagliptin relaxes phenylephrine-contracted rabbit aortic rings through pharmacologically defined involvement of voltage-dependent potassium channels and the SERCA pump. The findings extend research on SK-0403 beyond glycemic control while indicating that the response is independent of endothelium, cAMP/PKA, and cGMP/PKG signaling.
-
Cisplatin (CDDP) Workflow for TNBC Research
2026-09-19
Build more informative Cisplatin experiments by pairing DNA-damage cytotoxicity with apoptosis, oxidative-stress, and PD-L1–GRP78 measurements. This workflow helps distinguish direct cell killing from adaptive signaling in triple-negative breast cancer and chemotherapy resistance studies.
-
X-Gal Workflows for Cloning and Reporter Assays
2026-09-18
Turn lacZ activity into a practical visual decision point for molecular cloning, colony selection, and reporter validation. This guide pairs an optimized X-Gal workflow with a cautious extension to olfactory-receptor research inspired by the iRhom2 study.
-
Trelagliptin succinate Research Workflows
2026-09-18
Learn how Trelagliptin succinate supports reproducible DPP-4, metabolic, inflammatory, bone, and diabetes-associated cognition studies. Practical concentration windows, model-selection guidance, and troubleshooting strategies help translate glucose-lowering activity into pathway-level assays.
-
Elobixibat hydrate: IBAT Assay Workflows
2026-09-17
Build reproducible gastrointestinal and metabolic assays with Elobixibat hydrate, an ileal bile acid transporter inhibitor designed to increase colonic bile acid signaling. This guide connects stock preparation, intestinal motility, TGR5–GLP-1 readouts, and troubleshooting to practical research use cases without confusing clinical dosing with experimental conditions.
-
circSPECC1–miR-1236-3p–CBX8 in Breast Cancer
2026-09-17
The reference study identifies circSPECC1 as a radiation-responsive circular RNA that supports breast cancer cell growth partly through the miR-1236-3p/CBX8 axis. Its combination of patient tissues, cell-based perturbation, mechanistic RNA assays, and xenograft validation provides a useful framework for studying noncoding RNA contributions to radiotherapy response.
-
Trelagliptin succinate: Reliable Cell Assays
2026-09-16
This scenario-driven guide explains how Trelagliptin succinate, SKU A3889, can support better-controlled viability, inflammation, and signaling experiments. It connects concentration selection, stock preparation, assay interpretation, and vendor evaluation to published chondrocyte evidence and documented product specifications.
-
Topotecan HCl: From DNA Damage to Translation
2026-09-15
A mechanistic and strategic guide to using Topotecan HCl as a controllable topoisomerase 1 inhibitor, while connecting tumor DNA damage biology with emerging insights into selective neuronal vulnerability.
-
Talabostat mesylate: Applied Research Workflows
2026-09-15
Talabostat mesylate (PT-100) supports mechanism-led studies of DPP4, FAP, immune signaling, and tumor–stroma interactions rather than serving as a generic cytotoxic reagent. This guide connects FAP-selective cancer models with a reference-aligned NLRP1 assay strategy, including preparation, controls, troubleshooting, and interpretation limits.
-
Trifluoperazine 2HCl: Assay Workflows
2026-09-14
Build cleaner dopamine D2 receptor, ROS, and autophagy experiments with a practical workflow for Trifluoperazine 2HCl. This guide connects receptor pharmacology with macrophage host-directed assays while separating established evidence from testable cross-domain hypotheses.
-
Talabostat mesylate: FAP and DPP4 Workflows
2026-09-14
Talabostat mesylate enables mechanistic studies of DPP4 and FAP activity across tumor, stromal, immune, and hematopoietic models. This guide connects PT-100 assay design with the reference study’s NLRP1 findings while emphasizing target validation, controls, and interpretation limits.
-
BML-277: Selective Chk2 Inhibitor Guide
2026-09-13
BML-277 is a potent Chk2 inhibitor with reported nanomolar biochemical activity and micromolar cellular activity in radiation-exposed human T-cell studies. Its defined ATP-competitive profile makes it useful for DNA damage response research, but the compound should not be treated as direct proof of every downstream CHK2 mechanism.
-
(S)-(+)-Methoprene: JH Signaling Workflows
2026-09-12
Use (S)-(+)-Methoprene as a stage-sensitive juvenile hormone analog to separate receptor activation from endogenous hormone biosynthesis. This practical workflow connects Met signaling with metamorphosis, vitellogenesis, miRNA regulation, and insecticide mode-of-action studies while emphasizing solvent control and troubleshooting.
-
Ruxolitinib (INCB018424): JAK1/2 Research
2026-09-12
Ruxolitinib, also called INCB018424, is an ATP-competitive JAK1/JAK2 inhibitor used in myelofibrosis research, myeloproliferative disorder research, and immune-profiling studies. Its biochemical selectivity and activity in progenitor-cell assays support pathway-focused experiments, while murine sarcoma data show that combination with oncolytic HSV can reshape intratumoral immune populations.
-
SNS-032: CDK Biology from Cancer to Host Factors
2026-09-11
SNS-032 (BMS-387032) is a potent CDK2, CDK7, and CDK9 inhibitor whose value extends beyond target potency to mechanistic assay design. This article connects RNA polymerase II phosphorylation, cancer phenotypes, and emerging host-factor research while clearly separating established evidence from exploratory applications.